Nomilin

Nomilin is a limonoid triterpene compound found primarily in citrus fruits, particularly in the seeds and juice of oranges and lemons. It exerts its biological effects largely through modulation of nuclear factor-kappa B (NF-κB) signaling, activation of Nrf2-mediated antioxidant pathways, and interference with tumor cell proliferation cascades.

Origin & History

Nomilin is a limonoid triterpenoid found in citrus fruits like lemons, limes, oranges, and grapefruits, with grapefruit seeds being particularly rich sources. It appears as a yellow to off-white solid powder with limited solubility in common solvents.

Historical & Cultural Context

There is no information available regarding the historical or traditional medicinal uses of nomilin in any medical systems such as Ayurveda or Traditional Chinese Medicine.

Health Benefits

• Exhibits anti-inflammatory properties, as demonstrated in preclinical models.
• Acts as an antioxidant, based on in vitro studies.
• Shows potential as an anti-obesity agent in animal models.
• Demonstrates hypoglycemic effects in preclinical research.
• Functions as an antineoplastic agent, according to in vitro and animal studies.

How It Works

Nomilin suppresses inflammatory signaling by inhibiting NF-κB activation, thereby reducing downstream production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. It simultaneously activates the Nrf2/Keap1 pathway, upregulating phase II detoxification enzymes including heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1), which confer cellular antioxidant protection. Its antineoplastic activity involves induction of apoptosis via modulation of Bcl-2 family proteins and inhibition of MAPK/ERK signaling pathways, and its hypoglycemic effects are associated with improved insulin sensitivity and inhibition of α-glucosidase enzyme activity.

Scientific Research

There are no human clinical trials or meta-analyses available for nomilin. The research primarily consists of preclinical studies conducted in vitro and in animal models.

Clinical Summary

The evidence base for nomilin is currently limited almost entirely to in vitro cell studies and in vivo rodent models, with no published randomized controlled trials in humans as of 2024. Animal studies using doses ranging from approximately 10 to 50 mg/kg body weight have demonstrated reductions in fasting blood glucose, decreases in adipose tissue accumulation, and suppression of tumor growth in xenograft models. One preclinical anti-obesity study in high-fat diet-induced obese mice showed significant reductions in body weight and improvement in lipid profiles at 20 mg/kg. The overall evidence is promising but considered preliminary, and extrapolation to human dosing and efficacy requires considerable caution until clinical trials are conducted.

Nutritional Profile

Nomilin is a tetracyclic triterpenoid limonoid compound, not a conventional macronutrient or micronutrient source, and thus has no meaningful protein, fat, carbohydrate, fiber, vitamin, or mineral content in nutritional terms. It is found predominantly in citrus seeds and peel at concentrations ranging approximately 0.1–2.5 mg/g dry weight depending on species (highest in Citrus limon and Citrus aurantium). As a bioactive compound, its primary significance lies in its limonoid skeleton structure, which confers its biological activity. Oral bioavailability is considered moderate but limited by poor aqueous solubility; nomilin undergoes hepatic metabolism and is partially converted to nomilin glucoside in the intestinal tract, which may serve as a bioavailable reservoir form. Absorption is enhanced in the presence of dietary fats due to its lipophilic character. Typical experimental doses in animal studies range from 25–100 mg/kg body weight, with no established human dietary reference intake.

Preparation & Dosage

No clinically studied dosage ranges or forms are available for nomilin due to the lack of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Nomilin pairs well with hesperidin (a citrus flavanone), as both compounds share complementary NF-κB inhibitory and Nrf2-activating pathways, producing additive anti-inflammatory and antioxidant effects while hesperidin's better aqueous solubility may aid co-formulation stability. Quercetin enhances nomilin's antineoplastic activity through synergistic modulation of apoptotic signaling (specifically Bcl-2/Bax ratio and caspase-3 activation) and additive inhibition of PI3K/Akt pathways observed in shared in vitro cancer models. Berberine complements nomilin's hypoglycemic and anti-obesity mechanisms through distinct but additive actions — nomilin suppresses hepatic lipogenesis via SREBP-1c modulation while berberine activates AMPK, together improving insulin sensitivity across multiple metabolic nodes. Additionally, piperine (from black pepper) at approximately 5–20 mg doses may enhance nomilin's oral bioavailability by inhibiting CYP3A4-mediated first-pass metabolism and P-glycoprotein efflux, a mechanism well-documented for co-administration with similarly lipophilic bioactives.

Safety & Interactions

No formal human clinical safety trials for isolated nomilin supplementation have been published, making it difficult to establish a definitive safety profile or tolerable upper intake level. In animal studies, nomilin has been generally well tolerated at research doses, but high concentrations of citrus limonoids as a class have demonstrated potential hepatotoxic effects in some rodent models, warranting caution. Nomilin may theoretically interact with cytochrome P450 enzymes, particularly CYP3A4, similar to other citrus-derived compounds, potentially altering the metabolism of drugs such as statins, immunosuppressants, and calcium channel blockers. Pregnant or breastfeeding individuals and those with liver conditions should avoid isolated nomilin supplements until human safety data is available.